CA-TRICENTIS
15.1.2020 19:24:05 CET | Business Wire | Press release
Tricentis, the leader in continuous testing for DevOps, announced that it has acquired SpecFlow, the biggest and most trusted BDD solution for .NET developers around the world. SpecFlow’s pragmatic approach to specification-by-example has helped agile development teams improve collaboration with business stakeholders to build and deliver higher quality software.
SpecFlow will continue to remain a free, open source offering for the software development and testing communities. SpecFlow+ , SpecFlow’s commercial offering, and SpecMap , an Azure DevOps extension for user story mapping, will now be offered for free to meet the needs of scaling BDD across the enterprise – all backed by Tricentis’ leading innovation in continuous testing.
With this acquisition, Tricentis continues to extend its leadership in the open source and developer-led testing market. SpecFlow is Tricentis’ second acquisition in this market within the past year, with further acquisitions planned in the coming months. In 2019, Tricentis acquired TestProject , the world’s first free, cloud based test automation platform leveraging Selenium and Appium. The acquisition of SpecFlow adds best-in-class support for BDD and .NET developers to round out Tricentis’ comprehensive open source testing platform.
“BDD is becoming broadly relevant in enterprises for their digital transformation,” explained Tricentis Founder and Chief Strategy Officer Wolfgang Platz. “As business requirements change at DevOps speed, teams need a way to document how their applications should behave across highly integrated systems. Without built-in test automation to this shared understanding, software delivery leads to production bugs and poor user experiences. SpecFlow’s ability to create this shared business understanding, connected with automated tests, makes it the most trusted BDD platform for .NET development.”
SpecFlow was developed by TechTalk as the open source port of Cucumber for .NET in 2009. Since then, SpecFlow has gathered a massive open source community, with more than 9.6 million downloads and a user base that continues to grow at more than 3,000 downloads per day.
SpecFlow provides a way to define, manage and automatically execute human-readable acceptance tests in .NET projects. By using human-readable syntax, known as Gherkin (“Given-When-Then”), SpecFlow helps software delivery teams to create a common business understanding of how their systems should behave. Its integration with popular developer tools like Selenium and Microsoft Visual Studio have made SpecFlow the BDD standard to bridge the communication gap between developers, testers and business users.
“I’m extremely proud of the community that SpecFlow has fostered over the years,” said Christian Hassa, Owner and Managing Partner at TechTalk. “TechTalk is happy to have found a partner in Tricentis who is committed to the BDD community and to significantly expand on our vision for SpecFlow while keeping it independent.”
About SpecFlow
SpecFlow is the world’s leading open-source Behavior-Driven Development framework for .NET. SpecFlow facilitates collaboration between teams in small and large enterprises, allows you to automate tests written in human-readable language, and helps stakeholders build up a shared understanding of software systems. Learn more about SpecFlow at https://specflow.org .
About TechTalk
TechTalk is a Central European company that specializes in agile methods, agile development, and agile coaching. TechTalk was a first mover in the agile community, realized the potential of Behavior-Driven Development at an early stage and started developing SpecFlow in 2008. TechTalk released SpecFlow as an open-source project in 2009 to involve the agile community and accelerate the growth and adoption of SpecFlow. Learn more about TechTalk at https://techtalk.at or follow us on LinkedIn , Twitter .
About Tricentis
With the industry’s #1 Continuous Testing platform, Tricentis is recognized for reinventing software testing for DevOps. Through agile test management and advanced test automation optimized to support over 150+ technologies, we provide automated insight into the business risks of your software releases–transforming testing from a roadblock to a catalyst for innovation. The result is accelerated software delivery speed, improved cost efficiency, and reduced business risk.
Tricentis is the only vendor to achieve “Leader” status in all three top analyst reports (i.e., the “Triple Crown”). This honor is based on our technical leadership, innovation, and a Global 2000 customer base of 1600+ companies, including global enterprises such as Allianz, ANZ Bank, Cisco, Dolby, Experian, First Data, HSBC, Merck, Office Depot, Samsung, Swiss Re, Starbucks, Telstra, UBS, Vodafone, Whole Foods, and WorldPay. Customers rely on Tricentis to achieve and sustain test automation rates of over 90 percent–increasing risk coverage while accelerating testing to keep pace with Agile and DevOps.
Tricentis has a global presence in Austria, Australia, Belgium, Denmark, Germany, India, Netherlands, Singapore, Switzerland, Poland, United States and the UK. To learn more, visit https://www.tricentis.com or follow us on LinkedIn , Twitter , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005741/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom